Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Etokimab · ANB-020

Monoclonal antibody · developed by AnaptysBio

Phase 2 Most advanced trial (none active)

ANAB Developer

1 Registered trials

What is Etokimab?

Etokimab (also coded ANB020) is an investigational agent given as a one-hour intravenous infusion on Day 1.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ANB-020
Drug type: Monoclonal antibody
Therapy area: Respiratory
Developer: AnaptysBio, Inc. (ANAB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 7UWT6B0L2U

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03469934	Phase 2	Eosinophilic Asthma	Completed	ANAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Eosinophilic Asthma

More from AnaptysBio

ANB032 Phase 2 Rosnilimab Phase 2

Sources

ClinicalTrials.gov NCT03469934

Updated Oct 11, 2026. Something wrong or missing? Report it on the ANAB page.

Follow ANAB, the company behind Etokimab

See ANAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ANAB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z